NCT00160524
Who may be able to join
Who might be able to join this trial:
- You must have already taken part in one of two specific earlier studies (called CDP870-031 or CDP870-032) and completed it at the 26-week point, whether you received the active treatment, a dummy treatment (placebo), or both.
- You must be able to understand the information given to you about the trial and sign a written consent form agreeing to take part.
Who may not be able to join:
- If there was any reason you would not have been allowed to join the earlier qualifying study (CDP870-031 or CDP870-032), that same reason may stop you from joining this trial — please check with the trial site for details on what those reasons were.
- Note: having previously taken part in a clinical trial of the medicine called Certolizumab Pegol does not automatically exclude you from this trial (confirm with trial site).
- There is no restriction based on how active or severe your condition is at the time of joining this trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
14 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study CDP870-033 (up to 84 Months); Percentage of Subjects With at Least One Serious Adverse Event (SAE) During the Duration of This Study CDP870-033 (up to 84 Months)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.